Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 6 Urinary Bladder Neoplasms 3 Stomach Neoplasms 3 Ovarian Neoplasms 2 Carcinoma, Transitional Cell 2 Triple Negative Breast Neoplasms 1 Rectal Neoplasms 1 Neoplasms 1 Muscle Invasive Bladder Cancer (MIBC) 1 Head and Neck Neoplasms 1 HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1 HER2-low Breast Cancer 1 Gastric Adenocarcinoma 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1 Advanced Breast Cancer 1

Interventions

apatinib 2 Hyperthermic Intraperitoneal Chemotherapy 2 Gastrectomy 2 trastuzumab deruxtecan 1 taxane 1 sintilimab 1 pembrolizumab 1 durvalumab 1 disitamab vedotin 1 cabozantinib 1 Taxes 1 Tadalafil 1 SHR-1701 1 S 1 (combination) 1 Platinum 1 Paclitaxel 1 Oxaliplatin 1 Magnetic Resonance Spectroscopy 1 Indocyanine Green 1 Immunotherapy, Adoptive 1 Cytoreduction Surgical Procedures 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1 1,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Gastric Adenocarcinoma × disitamab vedotin × 1 year × Clear all

NCT07507526 2026-04-02

DTP-HER2

Sun Yat-sen University

Phase 2 Not yet recruiting

Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡